119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination
暂无分享,去创建一个
Shinn-Jang Hwang | M. Lievens | C. Liu | T. Schwarz | C. Fogarty | Phoebe Nakanwagi | M. Yono | J. Ervin | C. Maréchal | C. Andrews | Tamara Eckermann | K. Takazawa | Veronica Hulstrøm | Pedro P Ylisastigui | Miguel Vicco